Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
Marwan Fakih, Lisa Salvatore, Taito Esaki, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 23, pp. 2125-2139
Closed Access | Times Cited: 157

Showing 1-25 of 157 citing articles:

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
Antonio Passaro, Maise Al Bakir, Emily G. Hamilton, et al.
Cell (2024) Vol. 187, Iss. 7, pp. 1617-1635
Open Access | Times Cited: 124
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
M.F. Mosele, C. Benedikt Westphalen, A Stenzinger, et al.
Annals of Oncology (2024) Vol. 35, Iss. 7, pp. 588-606
Open Access | Times Cited: 80
Targeting KRAS in cancer
Anupriya Singhal, Bob T. Li, Eileen M. O’Reilly
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 969-983
Closed Access | Times Cited: 67
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
Jayesh Desai, Guzmán Alonso, Se Hyun Kim, et al.
Nature Medicine (2023) Vol. 30, Iss. 1, pp. 271-278
Open Access | Times Cited: 53
Targeting cytokine and chemokine signaling pathways for cancer therapy
Ming Yi, Tianye Li, Mengke Niu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 49
Colorectal cancer
Cathy Eng, Takayuki Yoshino, Érika Ruiz-García, et al.
The Lancet (2024) Vol. 404, Iss. 10449, pp. 294-310
Closed Access | Times Cited: 47
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
Míriam Molina‐Arcas, Julian Downward
Cancer Cell (2024) Vol. 42, Iss. 3, pp. 338-357
Open Access | Times Cited: 46
Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial
Yasutoshi Kuboki, Marwan Fakih, John H. Strickler, et al.
Nature Medicine (2024) Vol. 30, Iss. 1, pp. 265-270
Open Access | Times Cited: 34
Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
Rona Yaeger, Nataliya V. Uboha, Meredith S. Pelster, et al.
Cancer Discovery (2024) Vol. 14, Iss. 6, pp. 982-993
Open Access | Times Cited: 28
Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer
Patrick W. Underwood, Samantha M. Ruff, Timothy M. Pawlik
Cells (2024) Vol. 13, Iss. 3, pp. 245-245
Open Access | Times Cited: 24
Combinatorial strategies to target RAS-driven cancers
Naiara Perurena, Lisa Situ, Karen Cichowski
Nature reviews. Cancer (2024) Vol. 24, Iss. 5, pp. 316-337
Closed Access | Times Cited: 22
Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
William H. Gmeiner
Cancers (2024) Vol. 16, Iss. 5, pp. 1029-1029
Open Access | Times Cited: 17
Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver
Javier Ros, Caterina Vaghi, Iosune Baraibar, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3304-3304
Open Access | Times Cited: 15
KRAS G12C inhibitor combination therapies: current evidence and challenge
Hirotaka Miyashita, Shumei Kato, David S. Hong
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 15
Molecular principles underlying aggressive cancers
Ruth Nussinov, Bengi Ruken Yavuz, Hyunbum Jang
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 3
Targeting the EGFR signalling pathway in metastatic colorectal cancer
Stefania Napolitano, Giulia Martini, Davide Ciardiello, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 7, pp. 664-676
Closed Access | Times Cited: 13
Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer
Nadia Saoudi, Javier Ros, Iosune Baraibar, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 412-412
Open Access | Times Cited: 12
Consensus, debate, and prospective on pancreatic cancer treatments
Junke Wang, Jie Yang, Amol Narang, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 11
State-of-the-Art Management of Colorectal Cancer: Treatment Advances and Innovation
Priyadarshini Pathak, Gloria Chan, Dustin A. Deming, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 10
The Advent of Molecular Targeted Therapies Against Cancer. Toward Multi‐Targeting Drugs Through Materials Engineering: A Possible Future Scenario
Marianna Puzzo, Marzia De Santo, Catia Morelli, et al.
Small Science (2024) Vol. 4, Iss. 8
Open Access | Times Cited: 9
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Sílvia Casacuberta‐Serra, Íñigo González-Larreategui, Daniel Capitán-Leo, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 8
Management of metastatic colorectal cancer: consensus in the Gulf Cooperation Council countries
Bazarbashi Shouki, Ahmed Abdelsalam, Amirul Al‐Ashraf Abdullah, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access | Times Cited: 1
Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT Trial embedded phase II population
Jenny F. Seligmann, Dion Morton, Faye Elliott, et al.
Annals of Oncology (2025)
Closed Access | Times Cited: 1
Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence?
Erika Stucchi, Michela Bartolini, Marco Airoldi, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 4, pp. 371-382
Open Access | Times Cited: 7
The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?
Yuko Oya, Kazuyoshi Imaizumi, Tetsuya Mitsudomi
Lung Cancer (2024) Vol. 194, pp. 107886-107886
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top